title: High-dose therapy and autologous stem cell transplantation for extra-nodal NK/T lymphoma in patients from the Western hemisphere: a study from the European Society for Blood and Marrow Transplantation.
abstract: Extra-nodal NK/T lymphoma (ENKTL) is rare and more frequently encountered in East Asia. The role of high-dose therapy and autologous stem cell transplantation (HDT-ASCT) for ENKTL is unclear. Twenty-eight evaluable patients who had undergone HDT-ASCT in Europe from 2000-2009 were studied. The median age was 47 years and patients had received a median of two lines of prior therapy. Some 57% of patients were not in complete remission or beyond first complete remission at HDT-ASCT. The 1-year non-relapse mortality (NRM) was 11%; 2-year progression-free survival (PFS) and overall survival (OS) rates were 41% and 52%, respectively. Notably, the 2-year PFS and OS for those with stage III/IV disease were 33% and 40%, respectively, with no relapses beyond 1-year post-HDT-ASCT. This is the largest analysis of HDT-ASCT for patients with ENKTL reported from the Western hemisphere. Survival is comparable to East Asian cohorts and outcomes are encouraging for patients with advanced disease.
authors.affiliation: a Clinical Haematology, Nottingham University Hospitals , Nottingham , UK.
authors.forename: Christopher P
authors.initials: CP
authors.lastname: Fox
authors.affiliation: b EBMT Lymphoma Working Party , Paris , France.
authors.forename: Ariane
authors.initials: A
authors.lastname: Boumendil
authors.affiliation: b EBMT Lymphoma Working Party , Paris , France.|c Department of Haematology , Asklepios Klinik St. Georg Hamburg , Germany.
authors.forename: Norbert
authors.initials: N
authors.lastname: Schmitz
authors.affiliation: b EBMT Lymphoma Working Party , Paris , France.
authors.forename: Herve
authors.initials: H
authors.lastname: Finel
authors.affiliation: b EBMT Lymphoma Working Party , Paris , France.
authors.forename: Jian J
authors.initials: JJ
authors.lastname: Luan
authors.affiliation: d Department of Haematology , Gazi University School of Medicine , Ankara , Turkey.
authors.forename: Gülsan
authors.initials: G
authors.lastname: Sucak
authors.affiliation: e Department of Haematology , Institute Paoli Calmettes , Marseille , France.
authors.forename: Didier
authors.initials: D
authors.lastname: Blaise
authors.affiliation: f Department of Haematology and Oncology , University Hospital Freiburg , Freiburg , Germany.
authors.forename: Jürgen
authors.initials: J
authors.lastname: Finke
authors.affiliation: g Department of Oncology/Haematology , DIAKO Bremen , Bremen , Germany.
authors.forename: Karl-Heinz
authors.initials: KH
authors.lastname: Pflüger
authors.affiliation: h Department of Haematology , Leiden University Medical Centre , Leiden , Netherlands.
authors.forename: Hendrik
authors.initials: H
authors.lastname: Veelken
authors.affiliation: i Department of Haematology , Hôpital Saint-Antoine and UPMC , Paris , France.
authors.forename: Norbert-Claude
authors.initials: NC
authors.lastname: Gorin
authors.affiliation: j Department of Haematology , Cliniques Universitaires Saint-Luc , Brussels , Belgium.
authors.forename: Xavier
authors.initials: X
authors.lastname: Poiré
authors.affiliation: k Department of Haematology , Haemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School , Hannover , Germany.
authors.forename: Arnold
authors.initials: A
authors.lastname: Ganser
authors.affiliation: b EBMT Lymphoma Working Party , Paris , France.|l Department Medicine V , University of Heidelberg , Germany.
authors.forename: Peter
authors.initials: P
authors.lastname: Dreger
authors.affiliation: b EBMT Lymphoma Working Party , Paris , France.|m Department of Haematology , Cambridge University Hospitals NHS Trust , Cambridge , UK.
authors.forename: Anna
authors.initials: A
authors.lastname: Sureda
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005060:Europe / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods; D006801:Humans; D054391:Lymphoma, Extranodal NK-T-Cell / Q000175:diagnosis / Q000453:epidemiology / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012042:Registries; D019233:Retreatment; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D055815:Young Adult
keywords: Epstein-Barr virus; high-dose therapy; natural killer cell lymphoma; stem cell transplantation